Literature DB >> 21330458

Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans.

Laura Rubbia-Brandt1, Sébastien Tauzin, Catherine Brezault, Céline Delucinge-Vivier, Patrick Descombes, Bertand Dousset, Pietro E Majno, Gilles Mentha, Benoit Terris.   

Abstract

Sinusoidal obstruction syndrome (SOS; formerly veno-occlusive disease) is a well-established complication of hematopoietic stem cell transplantation, pyrrolizidine alkaloid intoxication, and widely used chemotherapeutic agents such as oxaliplatin. It is associated with substantial morbidity and mortality. Pathogenesis of SOS in humans is poorly understood. To explore its molecular mechanisms, we used Affymetrix U133 Plus 2.0 microarrays to investigate the gene expression profile of 11 human livers with oxaliplatin-related SOS and compared it to 12 matched controls. Hierarchical clustering analysis showed that profiles from SOS and controls formed distinct clusters. To identify functional networks and gene ontologies, data were analyzed by the Ingenuity Pathway Analysis Tool. A total of 913 genes were differentially expressed in SOS: 613 being upregulated and 300 downregulated. Reverse transcriptase-PCR results showed excellent concordance with microarray data. Pathway analysis showed major gene upregulation in six pathways in SOS compared with controls: acute phase response (notably interleukin 6), coagulation system (Serpine1, THBD, and VWF), hepatic fibrosis/hepatic stellate cell activation (COL3a1, COL3a2, PDGF-A, TIMP1, and MMP2), and oxidative stress. Angiogenic factors (VEGF-C) and hypoxic factors (HIF1A) were upregulated. The most significant increase was seen in CCL20 mRNA. In conclusion, oxaliplatin-related SOS can be readily distinguished according to morphologic characteristics but also by a molecular signature. Global gene analysis provides new insights into mechanisms underlying chemotherapy-related hepatotoxicity in humans and potential targets relating to its diagnosis, prevention, and treatment. Activation of VEGF and coagulation (vWF) pathways could partially explain at a molecular level the clinical observations that bevacizumab and aspirin have a preventive effect in SOS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330458     DOI: 10.1158/1535-7163.MCT-10-1072

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  19 in total

Review 1.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

2.  Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.

Authors:  Si Xuan Koo; Sock Hoai Chan; Joanne Ngeow
Journal:  BMJ Case Rep       Date:  2016-01-04

3.  Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

Authors:  Roderich E Schwarz; Jordan D Berlin; Heinz J Lenz; Bernard Nordlinger; Laura Rubbia-Brandt; Michael A Choti
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

Review 4.  [Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)].

Authors:  A Tannapfel; A Reinacher-Schick; B Flott-Rahmel
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

5.  Differential expression of transcription factors and inflammation-, ROS-, and cell death-related genes in organotypic cultures in the modiolus, the organ of Corti and the stria vascularis of newborn rats.

Authors:  Johann Gross; Heidi Olze; Birgit Mazurek
Journal:  Cell Mol Neurobiol       Date:  2014-03-05       Impact factor: 5.046

6.  Effectiveness of oxaliplatin desensitization protocols.

Authors:  Susana Cortijo-Cascajares; Inmaculada Nacle-López; Ignacio García-Escobar; María José Aguilella-Vizcaíno; Alberto Herreros-de-Tejada; Hernán Cortés-Funes Castro; Miguel-Ángel Calleja-Hernández
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405

7.  Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.

Authors:  S M Robinson; J Mann; A Vasilaki; J Mathers; A D Burt; F Oakley; S A White; D A Mann
Journal:  J Hepatol       Date:  2013-04-23       Impact factor: 25.083

8.  The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.

Authors:  S M Robinson; D A Mann; D M Manas; F Oakley; J Mann; S A White
Journal:  Br J Cancer       Date:  2013-10-10       Impact factor: 7.640

9.  Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer.

Authors:  C P H Vreuls; S W M Olde Damink; G H Koek; A Winstanley; E Wisse; R H E Cloots; M A J van den Broek; C H C Dejong; F T Bosman; A Driessen
Journal:  Br J Cancer       Date:  2013-01-03       Impact factor: 7.640

10.  Treatment of neuroendocrine tumor liver metastases.

Authors:  Mark A Lewis; Timothy J Hobday
Journal:  Int J Hepatol       Date:  2012-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.